Cyclin D1 stimulation of estrogen receptor transcriptional activity independent of cdk4

Molecular and Cellular Biology

Volumn 17, Issue 9, 1997, Pages 5338-5347

  Neuman, Elizabeth ^a   Ladha, Mohamed H ^a   Lin, Nancy ^a   Upton, Todd M ^a   Miller, Susan J ^a   Direnzo, James ^a   Pestell, Richard G ^b   Hinds, Philip W ^a   Dowdy, Steven F ^c   Brown, Myles ^a   Ewen, Mark E ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYTAMOXIFEN; CYCLIN D1; CYCLIN DEPENDENT KINASE; ESTROGEN RECEPTOR; FULVESTRANT;

ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CELL CYCLE; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVATION; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; TRANSCRIPTION INITIATION;

EID: 0030745396     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.17.9.5338     Document Type: Article

References (62)

1. Adnane, J., P. Gaudray, M.-P. Simon, J. Simony-Lafontaine, P. Jeanteur, and C. Theillet. 1489. Proto-oncogene amplification and human breast cancer tumor phenotype. Oncogene 4:1389-1395.
2. Albanese, C., J. Johnson, G. Watanabe, N. Eklund, D. Vu, A. Arnold, and R. G. Pestell. 1995. Transforming p21ras mutants and c-Ets-2 activate the cyclin D1 promoter through distinguishable regions. J. Biol. Chem. 270: 23589-23597.
3. Bartkova, J., J. Lukas, H. Müller, D. Lüzhoft, M. Strauss, and J. Bartek. 1994. Cyclin D1 protein expression and function in human breast cancer. Int. J. Cancer 57:353-361.
4. Berns, E. M., J. G. Klijn, I. L. van Staveren, H. Portengen, E. Noordegraaf, and J. A. Foekens. 1992. Prevalence of amplification of oncogenes c-myc, HER2/neu, and int-2 in one thousand human breast tumours: correlation with steroid receptors. Eur. J. Cancer 28:697-700.
5. Berry, M., D. Metzger, and P. Chambon. 1990. Role of the two activating domains of the oestrogen receptor in the cell-type and promoter-context dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen. EMBO J. 9:2811-2818.
6. Borg, A., H. Sigurdsson, G. M. Clark, M. Ferno, S. A. Fuqua, H. Olsson, D. Killander, and W. L. McGurie. 1991. Association of INT2/HST1 coamplification in primary breast cancer with hormone-dependent phenotype and poor prognosis. Br. J. Cancer 63:136-142.
7. Brown, M. 1994. Estrogen receptor molecular biology. Hematol./Oncol. Clin. N. Am. 8:101-112.
8. Buckley, M. F., K. J. E. Sweeney, J. A. Hamilton, R. L. Sini, D. L. Manning, R. I. Nicholson, A. deFazio, C. K. W. Watts, E. A. Musgrove, and R. L. Sutherland. 1993. Expression and amplification of cyclin genes in human breast cancer. Oncogene 8:2127-2133.
9. Bunone, G., P. A. Briand, R. J. Miksicek, and D. Picard. 1996. Activation of the unliganded estrogen receptor by EOF involves the MAP kinase pathway and direct phosphorylation. EMBO J. 15:2174-2183.
10. Cavailles, V., S. Dauvois, F. L'Horset, G. Lopez, S. Hoare, P. J. Kushner, and M. G. Parker. 1995. Nuclear factor RIP140 modulates transcriptional activation by the estrogen receptor. EMBO J. 14:3741-3751.
11. Chakravarti, D., V. J. LaMorte, M. C. Nelson, T. Nakajima, I. G. Schulman, H. Juguilon, M. Montminy, and R. M. Evans. 1996. Role of CBP/P300 in nuclear receptor signalling. Nature 383:99-103.
12. Courjal, F., G. Louason, P. Speiser, D. Katsaros, R. Zeillinger, and C. Theillet. 1996. Cyclin gene amplification and overexpression in breast and ovarian cancers: evidence for the selection of cyclin D1 in breast and cyclin E in ovarian tumors. Int. J. Cancer 69:247-253.
13. Desprez, P.-Y., C. Roskelley, J. Campisi, and M. J. Bissell. 1993. Isolation of functional cell lines from a mouse mammary epithelial cell strain: the importance of basement membrane and cell-cell interaction. Mol. Cell. Diff. 1:99-110.
14. Dowdy, S. F., and P. W. Hinds. Unpublished observations.
15. Dowdy, S. F., P. W. Hinds, K. Louie, S. I. Reed, A. Arnold, and R. A. Weinberg. 1993. Physical interaction of the retinoblastoma protein with human D cyclins. Cell 73:499-511.
16. Ewen, M. E., C. J. Oliver, H. K. Sluss, S. J. Miller, and D. S. Peeper. 1995. p53-dependent repression of CDK4 translation in TGF-β-induced cell-cycle arrest. Genes Dev. 9:204-217.
17. Ewen, M. E., H. K. Sluss, C. J. Sherr, H. Matsushime, J.-Y. Kato, and D. M. Livingston. 1993. Functional interactions of the retinoblastoma protein with mammalian D-type cyclins. Cell 73:487-497.
18. Fantl, V., M. A. Richards, R. Smith, G. A. Lammie, G. Johnstone, D. Allen, W. Gregory, G. Peters, C. Dickson, and D. M. Barnes. 1990. Gene amplification on chromosome hand 11q13 and oestrogen receptor status in breast cancer. Eur. J. Cancer 26:423-429.
19. Fantl, V., G. Stamp, A. Andrews, I. Rosewell, and C. Dickson. 1995. Mice lacking cyclin D1 are small and show defects in eye and mammary gland development. Genes Dev. 9:2364-2372.
20. Fawell, S. E., R. White, S. Hoare, M. Sydenham, M. Page, and M. G. Parker. 1990. Inhibition of cstrogen receptor-DNA binding by the "pure" antiestrogen ICI 164.384 appears to be mediated by impaired receptor dimerization. Proc. Natl. Acad. Sci. USA 87:6883-6887.
21. Gillett, C., V. Fantl, R. Smith, C. Fisher, J. Bartek, C. Dickson, D. Barnes, and G. Peters. 1994. Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochcmical staining. Cancer Res. 54:1812-1817.
22. Graham, F. L., and A. van der Eb. 1973. A new technique for the assay of infectivity of human adcnovirus 5 DNA. J. Virol. 52:456-467.
23. Halachmi, S., E. Marden, G. Martin, H. MacKay, C. Abbondanza, and M. Brown. 1994. Estrogen receptor-associated proteins: possible mediators of hormone-induced transcription. Science 264:1455-1458.
24. Hall, M., and G. Peters. 1996. Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. Adv. Cancer Res. 68:67-108.
25. Hanstein, B., R. Eckner, J. DiRenzo, S. Halachmi, H. Liu, B. Searcy, R. Kurokawa, and M. Brown. 1996. p300 is a component of an estrogen receptor coactivator complex. Proc. Natl. Acad. Sci. USA 93:11540-11545.
26. Hinds, P. W., S. F. Dowdy, E. N. Eaton, A. Arnold, and R. A. Weinberg. 1994. Function of a human cyclin gene as an oncogene. Proc. Natl. Acad. Sci. USA 91:709-713.
27. Hinds, P. W., S. Mittnacht, V. Dulic, A. Arnold, S. I. Reed, and R. A. Weinberg. 1992. Regulation of retinoblastoma protein functions by ectopic expression of human cyclins. Cell 70:993-1006.
28. Hirai, H., and C. J. Sherr. 1996. Interaction of D-type cyclins with a novel myb-like transcription factor, DMP1. Mol. Cell. Biol. 16:6457-6467.
29. Kaelin, W. G., D. C. Pallas, J. A. DeCaprio, F. J. Kaye, and D. M. Livingston. 1991. Identification of cellular proteins that can interact specifically with the T/E1A-binding region of the retinoblastoma gene product. Cell 64:521-532.
30. Kamei, Y., L. Xu, T. Heinzel, J. Torchai, R. Kurokawa, B. Gloss, S.-C. Lin, R. A. Heyman, D. W. Rose, C. K. Glass, and M. G. Rosenfeld. 1996. A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors. Cell 85:403-414.
31. Kato, J.-Y., H. Matsushime, S. W. Hiebert, M. E. Ewen, and C. J. Sherr. 1993. Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase cdk4. Genes Dev. 7:331-342.
32. 1 cyclins D2 and D3 but not D1. Proc. Natl. Acad. Sci. USA 90:11513-11517.
33. Kato, S., H. Endoh, Y. Masuhiro, T. Kitamoto, S. Uchiyama, H. Sasaki, S. Masushige, Y. Gotoh, E. Nishida, H. Kawashima, D. Metzger, and P. Chambon. 1995. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 270:1491-1494.
34. Kumar, V., S. Green, G. Stack, M. Berry, J. R. Jin, and P. Chambon. 1987. Functional domains of the human estrogen receptor. Cell 51:941-951.
35. MAPK pathway. J. Biol. Chem. 271:20608-20616.
36. Le Douarin, B., C. Zechel, J. M. Garnier, Y. Lutz, L. Tora, P. Pierrat, D. Heery, H. Gronemeyer, P. Chambon, and R. Losson. 1995. The N-terminal part of TIF1, a putative mediator of the ligand-dependent activation function (AF-2) of nuclear receptors, is fused to B-raf in the oncogenic protein T18. EMBO J. 14:2020-2033.
37. Lee, J. W., F. Ryan, J. C. Swaffield, S. A. Johnston, and D. D. Moore. 1995. Interaction of thyroid-hormone receptor with a conserved transcriptional mediator. Nature 374:91-94.
38. Lovec, H., A. Sewing, F. C. Lucibello, R. Muller, and T. Moroy. 1994. Oncogenic activity of cyclin D1 revealed through cooperation with Ha-ras: link between cell cycle control and malignant transformation. Oncogene 9:323-326.
39. 1 control in retinoblastoma gene-deficient cells independently of cdk4 activity. Mol. Cell. Biol. 15:2600-2611.
40. Matsushime, H., D. E. Quelle, S. A. Shurtleff, M. Shibuya, C. J. Sherr, and J.-Y. Kato. 1994. D-type cyclin-dependent kinase activity in mammalian cells. Mol. Cell. Biol. 14:2066-2076.
41. Michalides, R., P. Hageman, H. van Tinteren, L. Houben, E. Wientjens, R. Klompmaker, and J. Peterse. 1996. A clinicopathological study on overexpression of cyclin D1 and of p53 in a series of 248 patients with operable breast cancer. Br. J. Cancer 73:728-734.
42. Migliaccio, A., M. Di Domenico, G. Castoria, A. de Falco, P. Bontempo, E. Nola, and F. Auricchio. 1996. Tyrosine kinase/p21ras/MAP-kinase pathway activation by estradiol-receptor complex in MCF-7 cells. EMBO J. 15:1292-1300.
43. Musgrove, E. A., J. A. Hamilton, C. S. L. Lee, K. J. E. Sweeney, C. K. W. Watts, and R. L. Sutherland. 1993. Growth factor, steroid, and steroid antagonist regulation of cyclin gene expression associated with changes in T-47D human breast cancer cell cycle progression. Mol. Cell. Biol. 13:3577-3587.
44. Neuman, E., M. H. Ladha, N. Lin, and M. E. Ewen. Unpublished observations.
45. Onate, S., S. Y. Tsai, M.-J. Tsai, and B. W. O'Malley. 1995. Sequence and characterization of a coactivator for the steroid hormone receptor super-family. Science 270:1354-1357.
46. Peeper, D. S., T. M. Upton, M. H. Ladha, E. Neuman, J. Zalvide, R. Bernards, J. A. DeCaprio, and M. E. Ewen. 1997. Ras signalling linked to the cell-cycle machinery by the retinoblastoma protein. Nature 386:177-181.
47. Schmidhauser, C., G. F. Casperson, C. A. Myers, K. T. Sanzo, S. Bolten, and M. J. Bissell. 1992. A novel transcriptional enhancer is involved in the prolactin- and extracellular matrix-dependent regulation of β-casein gene expression. Mol. Biol. Cell 3:699-709.
48. 1 cyclins. Cell 73:1059-1065.
49. 1 phase progression: cycling on cue. Cell 79:551-555.
50. Sherr, C. J. 1996. Cancer cell cycles. Science 274:1672-1677.
51. Sicinski, P., J. L. Donaher, Y. Geng, S. B. Parker, H. Gardner, M. Y. Park, R. L. Robker, J. S. Richards, L. K. McGinnis, J. D. Biggers, J. J. Eppig, R. T. Bronson, S. J. Elledge, and R. A. Weinberg. 1996. Cyclin D2 is an FSH-responsive gene involved in gonadal cell proliferation and oncogenesis. Nature 384:470-474.
52. Sicinski, P., J. L. Donaher, S. B. Parker, T. Li, A. Fazeli, H. Gardner, S. Z. Haslam, R. T. Bronson, S. Elledge, and R. A. Weinberg. 1995. Cyclin D1 provides a link between development and oncogenesis in the retina and breast. Cell 82:621-630.
53. Stepanova, L., X. Leng, S. B. Parker, and J. W. Harper. 1996. Mammalian p50Cdc37 is H protein kinase-targeting subunit of Hsp90 that binds and stabilizes Cdk4. Genes Dev. 10:1491-1502.
54. Tam, S. W., J. W. Shay, and M. Pagano. 1994. Differential expression and cell cycle regulation of the cyclin-dependent kinase 4 inhibitor p16Ink4. Cancer Res. 22:5816-5826.
55. vom Baur, E., C. Zechel, D. Heery, M. J. Heine, J. M. Garnier, V. Vivat, B. Le Douarin, H. Gronemeyer, P. Chambon, and R. Losson. 1996. Differential ligand-dependent interactions between AF-2 activating domain of nuclear receptors and the putative transcriptional intermediary factors mSUG1 and TIF1. EMBO J. 15:110-124.
56. Wang, T. C., R. D. Cardiff, L. Zukerberg, E. Lees, A. Arnold, and E. V. Schmidt. 1994. Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature 369:669-671.
57. Weinstat-Saslow, D., M. J. Merino, R. E. Manrow, J. A. Lawrence, R. F. Bluth, K. D. Wittenbel, J. F. Simpson, D. L. Page, and P. S. Steeg. 1995. Overexpression of cyclin D mRNA distinguishes invasive and in situ breast carcinomas from nonmalignant lesions. Nat. Med. 1:1257-1260.
58. Wilcken, N. R. C., B. Sarcevic, E. A. Musgrove, and R. L. Sutherland. 1996. Differential effects of retinoids and antiestrogens on cell cycle progression and cell cycle regulatory genes in human breast cancer cells. Cell Growth Differ. 7:65-74.
59. Yao, T.-P., G. Ku, N. Zhou, R. Scully, and D. M. Livingston. 1996. The nuclear hormone receptor coactiyator SRC-1 is a specific target of p300. Proc. Natl. Acad. Sci. USA 93:10626-10631.
60. Zhuang, Y., B. S. Katzenellenbogen, and D. J. Shapiro. 1995. Estrogen receptor mutants which do not bind 17β-estradiol dimerize and bind to the estrogen response element in vivo. Mol. Endocrinol. 9:457-466.
61. Zukerberg, L. R., W. I. Yang, M. Gadd, A. D. Thor, F. C. Koerner, E. V. Schmidt, and A. Arnold. 1995. Cyclin D1 (PRAD1) protein expression in breast cancer: approximately one-third of infiltrating mammary carcinomas show overexpression of the cyclin D1 oncogene. Mod. Pathol. 8:560-567.
62. Zwijsen, R. M. L., E. Wientjens, R. Klompmaker, J. van der Sman, R. Bernards, and R. J. A. M. Michalides. 1997. CDK-independent activation of estrogen receptor by cyclin D1. Cell 88:405-415.